| Dr Michael D Gabbard Ii, MD | |
|
1115 Ronald Reagan Pkwy Ste 148, Avon, IN 46123-6913 | |
| (317) 817-1636 | |
| Not Available |
| Full Name | Dr Michael D Gabbard Ii |
|---|---|
| Gender | Male |
| Speciality | Orthopedic Surgery |
| Experience | 10 Years |
| Location | 1115 Ronald Reagan Pkwy Ste 148, Avon, Indiana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053739508 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207XS0114X | Orthopaedic Surgery - Adult Reconstructive Orthopaedic Surgery | 59157 (Tennessee) | Secondary |
| 207X00000X | Orthopaedic Surgery | 01083955A (Indiana) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Indiana University Health Home Care | Indianapolis, IN | Home health agency |
| Suburban Home Health Llc | Noblesville, IN | Home health agency |
| Iu Health West Hospital | Avon, IN | Hospital |
| Indiana University Health | Indianapolis, IN | Hospital |
| Hendricks Regional Health | Danville, IN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Indiana University Health Care Associates Inc | 5799755864 | 882 |
News Archive
Lightpoint Medical, a clinical-stage medical device company developing advanced imaging technologies for intraoperative cancer detection, announced today that the company has signed an exclusive global license agreement for a molecular imaging technology called Beta Emission Tomography, developed by Professor Harrison Barrett, Regents Professor of Radiology and Optical Science, with his student Yijun Ding and colleague Dr. Luca Caucci at the University of Arizona Center for Gamma Ray Imaging.
Researchers at Columbia University's Mailman School of Public Health have released findings identifying factors that affected evacuation from the World Trade Center (WTC) Towers on September 11.
Scientists from an international consortium have identified a large number of new genetic markers that predispose individuals to lupus.
Treating patients who had early-stage triple-negative breast cancer with the chemotherapy agent capecitabine after they completed surgery and standard chemotherapy did not significantly improve disease-free or overall survival compared with observation, according to data from the randomized, phase III GEICAM/CIBOMA clinical trial presented at the 2018 San Antonio Breast Cancer Symposium, held Dec. 4-8.
Neurobiological Technologies, Inc. (Nasdaq: NTII) ("NTI") announced today that, on September 15, 2009, it received a letter from The Nasdaq Stock Market indicating that the bid price of NTI's common stock has closed below $1.00 per share for 30 consecutive business days.
› Verified 5 days ago
| Entity Name | Indiana University Health Care Associates Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1902032832 PECOS PAC ID: 5799755864 Enrollment ID: O20040727000955 |
News Archive
Lightpoint Medical, a clinical-stage medical device company developing advanced imaging technologies for intraoperative cancer detection, announced today that the company has signed an exclusive global license agreement for a molecular imaging technology called Beta Emission Tomography, developed by Professor Harrison Barrett, Regents Professor of Radiology and Optical Science, with his student Yijun Ding and colleague Dr. Luca Caucci at the University of Arizona Center for Gamma Ray Imaging.
Researchers at Columbia University's Mailman School of Public Health have released findings identifying factors that affected evacuation from the World Trade Center (WTC) Towers on September 11.
Scientists from an international consortium have identified a large number of new genetic markers that predispose individuals to lupus.
Treating patients who had early-stage triple-negative breast cancer with the chemotherapy agent capecitabine after they completed surgery and standard chemotherapy did not significantly improve disease-free or overall survival compared with observation, according to data from the randomized, phase III GEICAM/CIBOMA clinical trial presented at the 2018 San Antonio Breast Cancer Symposium, held Dec. 4-8.
Neurobiological Technologies, Inc. (Nasdaq: NTII) ("NTI") announced today that, on September 15, 2009, it received a letter from The Nasdaq Stock Market indicating that the bid price of NTI's common stock has closed below $1.00 per share for 30 consecutive business days.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Michael D Gabbard Ii, MD 250 N Shadeland Ave Ste 200, Indianapolis, IN 46219-4959 Ph: () - | Dr Michael D Gabbard Ii, MD 1115 Ronald Reagan Pkwy Ste 148, Avon, IN 46123-6913 Ph: (317) 817-1636 |
News Archive
Lightpoint Medical, a clinical-stage medical device company developing advanced imaging technologies for intraoperative cancer detection, announced today that the company has signed an exclusive global license agreement for a molecular imaging technology called Beta Emission Tomography, developed by Professor Harrison Barrett, Regents Professor of Radiology and Optical Science, with his student Yijun Ding and colleague Dr. Luca Caucci at the University of Arizona Center for Gamma Ray Imaging.
Researchers at Columbia University's Mailman School of Public Health have released findings identifying factors that affected evacuation from the World Trade Center (WTC) Towers on September 11.
Scientists from an international consortium have identified a large number of new genetic markers that predispose individuals to lupus.
Treating patients who had early-stage triple-negative breast cancer with the chemotherapy agent capecitabine after they completed surgery and standard chemotherapy did not significantly improve disease-free or overall survival compared with observation, according to data from the randomized, phase III GEICAM/CIBOMA clinical trial presented at the 2018 San Antonio Breast Cancer Symposium, held Dec. 4-8.
Neurobiological Technologies, Inc. (Nasdaq: NTII) ("NTI") announced today that, on September 15, 2009, it received a letter from The Nasdaq Stock Market indicating that the bid price of NTI's common stock has closed below $1.00 per share for 30 consecutive business days.
› Verified 5 days ago
Dr. Mark D Webster, MD Orthopedic Surgery Medicare: Medicare Enrolled Practice Location: 1115 Ronald Reagan Pkwy, Suite 148, Avon, IN 46123 Phone: 317-274-7273 Fax: 317-278-5494 |